Following fields are empty!

1
Search
2
Select
3
Submit
154
Journals
Page 1 of 8
Go to Next Page

Request Journal

Please fill in the form to request a new journal to be added. We will review your request and add it to the Journal Guide as soon as possible.

*

AIDS Research and Therapy

eISSN: 1742-6405
DOAJ Logo
SIGAPS Level D
Publisher: BioMed Central
Visit Publisher homepageVisit journal homepage
Molecular MedicineVirologyInfectious DiseasesPharmacology (medical)

AIDS Research and Therapy is an open access, peer reviewed journal publishing basic science and clinically important research articles to help abate the spread of AIDS. The journal is edited by Kailash C. Gupta with the assistance of an expert Editorial Board, including Deputy Editor Greg T. Spear, and Section Editors Edward A. Berger (Basic Science), Genoveffa Franchini (Vaccines), Magnus Gisslen (Neuro-AIDS), Richard Koup (Therapeutics), and John J. Rossi (Novel treatment strategies).

Read more
Loading data ...
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Go to Journal

ASSAY and Drug Development Technologies

ISSN: 1540-658XeISSN: 1557-8127
SIGAPS Level D
Publisher: Mary Ann Liebert
Visit Publisher homepageVisit journal homepage
Molecular MedicineDrug Discovery

ASSAY and Drug Development Technologies is the only authoritative, peer-reviewed journal that provides early-stage screening techniques and tools that enable you to optimize and identify novel leads and targets for new drug development.Each issue includes: Assay design and target development High throughput technologies and chemistry Technology reviews Lab automation and sample management Data analysis and information management Bioinformatics, data mining, and virtual screening Biosensors and detection technologies Miniaturization, microfluidics, and nanotechnology Novel screening methods with high information content Metabolically engineered cells and organisms Imaging technologies for live cells, tissues, and small animals.

Read more
Loading data ...
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Go to Journal

Acta Naturae

ISSN: 2075-8251
SIGAPS Level E
Publisher: Park Media Ltd.
BiochemistryBiotechnologyCell BiologyMolecular BiologyMolecular Medicine
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Advances in Biological Regulation

eISSN: 2212-4926
Publisher: Elsevier
Visit Publisher homepageVisit journal homepage
Cancer ResearchGeneticsMolecular BiologyMolecular Medicine

Advances in Biological Regulation (formerly Advances in Enzyme Regulation) reports cutting edge scientific progress on regulation at the molecular level, covering:The molecular biology of control of gene expression by hormones, drugs and growth factors in cancer cells and in clinical situations of metabolic diseases, inborn errors of metabolism and neoplasia.Stem cell biology and regenerative medicine issuesRegulatory networks, mainly in cellular signalling, differentiation, cell cycle & growth control, structure-function relationships, cell fate and lineage commitment or assembly mechanisms in cellsViruses, or supramolecular constructs, and signaling mechanisms mediating transcriptionGenomic, proteomic, bioinformatics and systems biology approaches to identify and characterize steps of biological control in a cellular context.Complex cellular, pathogenic, clinical, or animal model systems studied by biochemical, molecular, genetic, epigenetic or quantitative ultrastructural approachesBenefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Read more
Loading data ...
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Institutional Agreement

Tous les auteurs correspondants des Hospices Civils de Lyon ont la possibilité de publier leurs articles de recherches en Open Access dans cette revue. Pour bénéficier de cette prise en charge, déclarez les "Hospices Civils de Lyon" dans votre affiliation principale et utilisez votre adresse mail "@chu-lyon.fr" lors de la soumission de votre article.

ATTENTION:

  • Si l'éditeur vous demande de sélectionner la licence applicable, privilégiez la licence CC-BY à toutes autres.
  • Pour les revues non éligibles, dont The Lancet et les revues Cell Press, ou en cas d’épuisement du stock de droits, la publication en accès ouvert immédiat devient payante mais de manière optionnelle ; le tarif bénéficie dans ce cas d’une remise de 10%.
  • Les articles publiés en accès ouvert immédiat au titre de l’accord peuvent être déposés dans leur version finale éditeur dans une archive ouverte, par exemple dans HAL-HCL.
  • Dans le cas des articles sous abonnement, il est permis par la Loi République numérique de déposer dans une archive ouverte le manuscrit auteur accepté d’un article et de le diffuser avec un embargo de 6 mois (sciences dures) ou 12 mois (SHS).

Si vous rencontrez des difficultés ou si vous avez des questions, contactez la Documentation Centrale sur sa.documentationcentrale@chu-lyon.fr ou au 04-72-11-29-99 (31-29-99)